Company Analysis
Sign in

BridgeBio Pharma, Inc. (BBIO)

Nasdaq: BBIO · Pharmaceutical Preparations · Palo Alto, CA · filing with the SEC since 2018
Full chart Alerts Compare
Grade6.2
◀ Past 6.4● Present 6.4▶ Future 5.7
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

23 patents granted to the 24 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to BridgeBio Pharma, Inc.’s names, not what it holds today.

Patents granted
23
23 utility, 1976 to Dec 31, 2025
Granted in 2025
4
Against 5 in 2024 and 3 in 2023
Applications published
66
13 of them in 2025
Names they are printed under
24
a subsidiary
By yearGrantedApplications published
'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals10
Organic fine chemistry8
Analysis of biological materials1
Biotechnology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name24 counted
EIDOS THERAPEUTICS, INC. a subsidiary
named as the applicant on its applications, in US
0 granted
11 published
PHOENIX TISSUE REPAIR, INC. a subsidiary
named as the applicant on its applications, in US
0 granted
10 published
Ferro Therapeutics, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
8 published
EIDOS THERAPEUTICS, INC. a subsidiary
US, as the owner printed on each patent
7 granted
0 published
BridgeBio Services Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
5 published
COA THERAPEUTICS, INC. a subsidiary
named as the applicant on its applications, in US
0 granted
5 published
NAVIRE PHARMA, INC. a subsidiary
named as the applicant on its applications, in US
0 granted
5 published
QED Therapeutics, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
4 published
Adrenas Therapeutics, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
3 published
BridgeBio Gene Therapy Research, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
3 published
CALCILYTIX THERAPEUTICS, INC. a subsidiary
named as the applicant on its applications, in US
0 granted
3 published
CANTERO THERAPEUTICS, INC. a subsidiary
named as the applicant on its applications, in US
0 granted
3 published
NAVIRE PHARMA, INC. a subsidiary
US, as the owner printed on each patent
3 granted
0 published
PHOENIX TISSUE REPAIR, INC. a subsidiary
US, as the owner printed on each patent
3 granted
0 published
VENTHERA, INC. a subsidiary
named as the applicant on its applications, in US
0 granted
3 published
COA THERAPEUTICS, INC. a subsidiary
US, as the owner printed on each patent
2 granted
0 published
Ferro Therapeutics, Inc. a subsidiary
US, as the owner printed on each patent
2 granted
0 published
MOLECULAR SKIN THERAPEUTICS, INC. a subsidiary
US, as the owner printed on each patent
2 granted
0 published
MOLECULAR SKIN THERAPEUTICS, INC. a subsidiary
named as the applicant on its applications, in US
0 granted
2 published
Adrenas Therapeutics, Inc. a subsidiary
US, as the owner printed on each patent
1 granted
0 published
CALCILYTIX THERAPEUTICS, INC. a subsidiary
US, as the owner printed on each patent
1 granted
0 published
ML Bio Solutions Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
1 published
QED Therapeutics, Inc. a subsidiary
US, as the owner printed on each patent
1 granted
0 published
VENTHERA, INC. a subsidiary
US, as the owner printed on each patent
1 granted
0 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Jul 15, 202512,357,632Methods of treating cholangiocarcinomaPharmaceuticalsQED Therapeutics, Inc.
Jul 15, 202512,357,576Formulations of triphenyl calcilytic compoundsPharmaceuticalsCALCILYTIX THERAPEUTICS, INC.
Apr 22, 202512,281,123Benzoxazinone compounds as KLK5/7 dual inhibitorsPharmaceuticalsMOLECULAR SKIN THERAPEUTICS, INC.
Jan 14, 202512,195,767Adeno-associated virus gene therapy for 21-hydroxylase deficiencyBiotechnologyAdrenas Therapeutics, Inc.
Aug 27, 202412,070,449Methods of treating TTR amyloidosis using AG10PharmaceuticalsEIDOS THERAPEUTICS, INC.
Jun 11, 202412,005,043Formulations of AG10PharmaceuticalsEIDOS THERAPEUTICS, INC.
Mar 19, 202411,932,643Substituted heterocyclic inhibitors of PTPN11Organic fine chemistryNAVIRE PHARMA, INC.
Mar 5, 202411,919,865Processes for preparing AG-10, its intermediates, and salts thereofOrganic fine chemistryEIDOS THERAPEUTICS, INC.
Feb 6, 202411,891,378Small molecule modulators of pantothenate kinasesOrganic fine chemistryCOA THERAPEUTICS, INC.
May 30, 202311,661,429Topical phosphoinositide 3-kinase inhibitorsPharmaceuticalsVENTHERA, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 9, 20252025/0313534PROCESSES FOR PREPARING AG-10, ITS INTERMEDIATES, AND SALTS THEREOFOrganic fine chemistryEIDOS THERAPEUTICS, INC.
Oct 2, 20252025/0304925ADENO-ASSOCIATED VIRUS GENE THERAPY FOR 21-HYDROXYLASE DEFICIENCYBiotechnologyAdrenas Therapeutics, Inc.
Aug 28, 20252025/0268900COMBINATION THERAPY USING A SUBSTITUTED PYRIMIDIN-4(3H)-ONE AND NIVOLUMAB AS WELL AS ITS USE IN THE TREATMENT OF CANCERPharmaceuticalsNAVIRE PHARMA, INC.
Jul 3, 20252025/0213563SUBSTITUTED PYRIMIDIN-4(3H)-ONES FOR USE IN TREATING CANCERPharmaceuticalsNAVIRE PHARMA, INC.
Jun 19, 20252025/0195520COMBINATION THERAPY USING A PTPN11 INHIBITOR AND AN EGFR INHIBITORPharmaceuticalsBridgeBio Services Inc.
Jun 12, 20252025/0188074PTPN11 INHIBITORSOrganic fine chemistryNAVIRE PHARMA, INC.
Apr 10, 20252025/0114480GENE THERAPY FOR GENETIC HEARING LOSSPharmaceuticalsBridgeBio Gene Therapy Research, Inc.
Mar 27, 20252025/0101002DEUTERATED INFIGRATINIB COMPOUNDSOrganic fine chemistryQED Therapeutics, Inc.
Mar 20, 20252025/0090526METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTORPharmaceuticalsCOA THERAPEUTICS, INC.
Feb 20, 20252025/0057811FORMULATIONS OF AG10PharmaceuticalsEIDOS THERAPEUTICS, INC.
What it applied for, 2024 to 2025: Pharmaceuticals 15 · Organic fine chemistry 6 · Biotechnology 2 · Measurement 1 · Analysis of biological materials 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton BBIO · research, not advice